S
Samuel Z. Goldhaber
Researcher at Brigham and Women's Hospital
Publications - 833
Citations - 76429
Samuel Z. Goldhaber is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Pulmonary embolism & Venous thrombosis. The author has an hindex of 124, co-authored 784 publications receiving 69216 citations. Previous affiliations of Samuel Z. Goldhaber include World Health Organization & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Clive Kearon,Elie A. Akl,Anthony J. Comerota,Paolo Prandoni,Henri Bounameaux,Samuel Z. Goldhaber,Michael E. Nelson,Philip S. Wells,Michael K. Gould,Francesco Dentali,Mark Crowther,Susan R. Kahn +11 more
TL;DR: Strong recommendations apply to most patients, whereas weak recommendations are sensitive to differences among patients, including their preferences.
Journal ArticleDOI
Acute pulmonary embolism: clinical outcomes in the international cooperative pulmonary embolism registry (ICOPER)
TL;DR: Data from ICOPER provide rates and highlight adverse prognostic categories that will help in planning of future trials of high-risk PE patients and highlight significant prognostic factors associated with death.
Journal ArticleDOI
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
Sam Schulman,Clive Kearon,Ajay K. Kakkar,Patrick Mismetti,Sebastian Schellong,Henry Eriksson,David Baanstra,Janet Schnee,Samuel Z. Goldhaber,S. Schul +9 more
TL;DR: For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfar in, and does not require laboratory monitoring.
Journal ArticleDOI
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Clive Kearon,Susan R. Kahn,Giancarlo Agnelli,Samuel Z. Goldhaber,Gary E. Raskob,Anthony J. Comerota +5 more
TL;DR: This chapter about treatment for venous thromboembolic disease is part of the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) and indicates that the benefits do or do not outweigh risks, burden, and costs.